Evidence map›Paper›PMID 36634280›Full record

ArticleHematology/oncology and stem cell therapy2023

Prophylactic Pretransplant Ganciclovir to Reduce Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation.

Daniel R Reed, Gina R Petroni, Melissa West, Caroline Jones, Abeer Alfaraj, Paige G Williams, Kathlene DeGregory, Kyle Grose, Sandra Monson, Indumathy Varadarajan and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology/oncology and stem cell therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Daniel R ReedSection of Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Health, Winston-Salem, NC, USA.
Gina R PetroniDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Melissa WestDepartment of Pharmacy, University of Virginia, Charlottesville, VA, USA.
Caroline JonesDepartment of Pharmacy, University of Virginia, Charlottesville, VA, USA.
Abeer AlfarajBayHealth Hematology/Oncology Associates, Delaware, PA, USA.
Paige G WilliamsDivision of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
Kathlene DeGregoryDepartment of Pharmacy, University of Virginia, Charlottesville, VA, USA.
Kyle GroseDepartment of Pharmacy, University of Kansas, Kansas City, KS, USA.
Sandra MonsonDepartment of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.
Indumathy VaradarajanDivision of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
Leonid VolodinDivision of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
Gerald R DonowitzDepartment of Infectious Disease, University of Virginia, Charlottesville, VA, USA.
Tamila L Kindwall-KellerDivision of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
Karen K BallenDivision of Hematology and Oncology, University of Virginia, Charlottesville, VA, USA.
University of Virginia · USAtrium Health Wake Forest Baptist · USHematology Oncology Associates · USUniversity of Kansas · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
NCI NIH HHS P30 CA044579
6 · The paper itself

Abstract

OBJECTIVE/

backgroundCytomegalovirus (CMV) reactivation remains a serious complication after allogeneic hematopoietic cell transplantation (HCT) occurring in approximately 60-70% of CMV-seropositive HCT recipients. CMV reactivation leads to adverse outcomes including end-organ damage, graft-versus-host disease, and graft failure.

methodsGanciclovir was administered pretransplant at 5 mg/kg twice daily intravenously from the start of conditioning to Day T-2 to CMV-seropositive patients receiving their first allogeneic HCT. CMV DNA was monitored weekly until at least Day 100 posttransplant.

resultsA total of 109 consecutive patients were treated, median age 57 (range 20-73) years. Of these, 36 (33%) patients had a CMV reactivation within the first 105 days posttransplant with a median time of reactivation of 52.5 (range 36-104) days posttransplant. The cumulative incidence of CMV reactivation at Day 105 posttransplant was 33.1% (95% confidence interval: 24.4-42.0). One patient developed CMV disease.

conclusionThe use of pretransplant ganciclovir was associated with low incidence of CMV reactivation and disease. These data suggest that pretransplant ganciclovir with preemptive therapy for viral reactivation may be a useful strategy to reduce CMV reactivation. Future prospective trials are needed to compare strategies for CMV prophylaxis.

Indexed as

Cytomegalovirus InfectionsGraft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultAgedCytomegalovirusGanciclovirHumansMiddle AgedYoung AdultGanciclovir

Identifiers

PMID36634280
PMCPMC11956836
OpenAlexW4248499721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.